Milena Bruzzone

A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.

Pierfranco Conté, Milena Bruzzone, S. Chiara et al. · Journal of Clinical Oncology · 1986 · 157 citations

Surgical Oncology, Epithelial Ovarian Cancer, Cancer Management +18

Intraperitoneal versus Intravenous Cisplatin in Combination with Intravenous Cyclophosphamide and Epidoxorubicin in Optimally Cytoreduced Advanced Epithelial Ovarian Cancer: A Randomized Trial of the Gruppo Oncologico Nord-Ovest

Angiolo Gadducci, F Carnino, S. Chiara et al. · Gynecologic Oncology · 2000 · 142 citations · Full text

Medicine, Metronomic Therapy, Gynecology +8

The incidence of narcotic-induced emesis

Elisabetta Campora, Laura Merlini, Maurizio Pace et al. · Journal of Pain and Symptom Management · 1991 · 131 citations · Full text

Substance Abuse, Psychoactive Drug, Addiction +8

High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest.

Pierfranco Conté, Milena Bruzzone, F Carnino et al. · Journal of Clinical Oncology · 1996 · 90 citations

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Ignace Vergote, Giovanni Scambia, David M. O’Malley et al. · The Lancet Oncology · 2019 · 85 citations · Full text

Advanced Ovarian Cancer, Medicine, Pharmacology +9